Welcome Guest
Home » Reports » T-Cell Immunotherapy Market, 2015-2030

T-Cell Immunotherapy Market, 2015-2030

Published: Oct 13, 2015
Pages: 419
Product Code: RA10047
License Type :  (Learn More)

[ - An updated version of this report is available at this link - ]

 

WHO has stated that the number of new cancer cases is expected to rise by 70% in the coming two decades. In the US alone, over one million people are diagnosed with cancer each year. Although cancer therapeutics continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. Specifically, immuno-oncology has been gradually nurtured by researchers over the last several years. Post an evident shift towards the development of therapeutics targeting cancer cells by harnessing immune system components, immunotherapeutics have gained a strong foothold in the pharmaceutical industry. After the early success of Immune Checkpoint Inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of this market.

 

Characterised by key features such as target specificity, adaptability and memory, T-cells have been effectively used as tools to mediate an immune response. T-cell immunotherapy is structured into segments comprising of CAR-T, TCR and TIL therapies. Academicians across the globe have significantly contributed by convening the initial research of the candidates; this has served as the framework for several start-ups / established industry players to drive the research forward.

 

The overall market is expected to make a huge leap over the coming decade. It is also important to highlight that various technology providers, aiming to develop T-cell immunotherapy products with improved efficacy and safety, have developed innovative platforms for engineering of the T-cells. Innovative research, lucrative rounds of VC funding, discovery of several novel targets, growing pipelines directed towards different therapeutic areas and encouraging clinical trial results have emerged as some of the other drivers of this market. 

 

[ - An updated version of this report is available at this link - ]

 
  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The “T-Cell Immunotherapy Market, 2015-2030” report provides an extensive study of the field of T-cell immunotherapy. With no marketed products, this emerging field is still in its infancy; the report provides a comprehensive view of the market segmented into the following three sub-groups: CAR-T therapies, TCR therapies and TIL therapies.

 

The market is characterised by a robust and opportunistic pipeline of products targeting both haematological cancers and solid tumours. As mentioned earlier, several research institutes have played a critical role in progression of the technology to its current stage. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania / The Children’s Hospital of Philadelphia), JCAR017 (Juno Therapeutics / Seattle Children’s Hospital), KTE-C19 and NY-ESO-1 TCR (Kite Pharma / National Cancer Institute), CD19-CAR (Takara Bio / Jichi Medical University) and LN-144 (Lion Biotechnologies / National Cancer Institute). Encouraging clinical results have accelerated the progress of these therapies as they have emerged as one of the most effective ways of leveraging the potential of immune system.

 

The market is also seeing a growing interest from several technology providers, especially those with capabilities in genome editing and viral and non-viral gene transfer. In addition, several T-cell immunotherapy companies and technology providers are also developing innovative safety switches to manage known side effects such as cytokine release syndrome and B-cell aplasia.

 

One of the key objectives of the study is to review and quantify the opportunities laid by the innovative programs of both small and big pharma firms. The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms. Amongst other elements, the report elaborates on the following key areas:

  • The current state of the market with respect to key players, development stage of pipeline products (both clinical / preclinical) and targeted indications
  • Partnerships which have taken place in the recent past covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms, product co-development and co-commercialisation
  • Innovative technological platforms, such as safety switches, which have contributed significantly in overcoming the existing gaps in therapy regimen
  • Various investments and grants received by the companies focused in this area
  • Therapeutic areas forming the current focus of developers, the gradual drift and opportunity offered by non-oncological therapeutic areas
  • Competitive landscape, challenges and expected trend of market evolution within the three sub-segments
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

 

The research, analysis and insights presented in this report include potential sales of several CAR-T therapies, TCR therapies and TIL therapies; this analysis is backed by a deep understanding of key drivers behind the growth. With most products still in the early stage of development, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

 

 

Example Highlights

  • During the course of our research, we identified over 180 T-cell therapies across various phases of development; CAR-T therapies (56%) are the most common, followed by TCR (25%) and TIL (19%) therapies.
  • Research institutions, through investment of time, expertise and effort, have played a critical role in the design and development of novel CAR-Ts, TCRs and TILs. In fact, non-industrial players are involved in the development of around 65% of all the molecules in the pipeline; of these, 23% molecules are being developed jointly with industry participants.
  • Kite Pharma is the current flag-bearer; Novartis, Juno Therapeutics, CBMG, Celyad, Lion Biotechnologies, Immunocore and Adaptimmune are some other well-known players. In addition, several start-ups have also emerged; these include (in alphabetical order) Altor BioScience, Applied Immune Technologies, Autolus, Carsgen, Celdara Medical, Eureka Therapeutics, Formula Pharmaceuticals, Mustang Therapeutics, Theravectys, TILT Biotherapeutics and TNK Therapeutics.
  • Engineered CAR-Ts with switch technologies are amongst the latest addition to the next-generation of T-cell immunotherapy pipeline. Players are developing CAR-Ts, TCRs and TILs which are more advanced and shall cater to a diverse array of patient needs. The coming few years are likely to witness a wave of innovative and successful T-cell therapies.
  • Funding from VC firms and strategic investors has been a key enabler to the market’s growth. Over the last six years, we identified investments close to USD 3 billion across several start-ups and small firms; this trend is unlikely to subside in the near future.
  • Overall, we believe the T-cell therapy market will be worth USD 30 billion by 2030, expanding at an annualised growth rate of over 100%; as TCR and TIL therapies gain ground, CAR-T therapies are likely to garner the most attention in near future.

 

 

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information. 

 

 

Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on where the T-cell immunotherapy market is headed in the mid-long term.

 

Chapter 3 provides a general introduction to T-cell immunotherapy. In this section, we have briefly discussed the conventional therapies being used for oncology treatment, the advent of cancer immunotherapy and the reasons supporting the gradual emergence of T-cell therapies.

 

Chapter 4 provides a comprehensive landscape of the T-cell immunotherapy market. It includes information on therapies which are currently in different stages of development (both clinical and preclinical/discovery). The detailed analysis of this pipeline includes information on most commonly targeted indications, current phases of development, the targets and the type of developers for each of the therapies.

 

Chapter 5 focuses on CAR-T based therapies and highlights the prevailing trends pertaining to the on-going research in this field. It discusses the targets under investigation, current challenges, toxicity issues and several other relevant parameters. To credit the work of the eminent researchers across the globe, we have provided a mapping of prominent key opinion leaders in the CAR-T space. The chapter includes detailed profiles of the drugs under development. These profiles cover information such as history of development, clinical trial timeline, clinical trial results, manufacturing, estimated cost of treatment and treatment regimen.

 

Chapter 6 elaborates on TCR based therapies and highlights the current scenario pertaining to the on-going research in this field. As with the CAR-T therapies, to credit the work of eminent researchers across the globe, we have provided a mapping of prominent key opinion leaders in the TCR space. The chapter also includes detailed drug profiles of several drugs under development.

 

Chapter 7 elaborates on the TIL based therapies. As in the earlier two chapters, we have mapped the prominent key opinion leaders in the TIL space. The chapter also includes detailed profiles of the drugs under development.

 

Chapter 8 elaborates on the monetary opportunity presented by these therapies. It provides a comprehensive market forecast analysis for molecules in advanced stages of development (phase I/II, phase II and phase II/III) taking into consideration the target patient population, competition, likely adoption rate and price points.

 

Chapter 9 provides a competitive landscape of various T-cell therapies being developed for the treatment of commonly targeted indications such as haematological cancers and solid tumours. These indications have been the prime focus of companies developing T-cell immunotherapies. The chapter also highlights the epidemiological facts and currently available treatments for each indication.

 

Chapter 10 talks about emerging technological platforms which mediate/assist the growth of the T-cell market. It includes a detailed discussion on such novel and innovative technologies, along with brief information about the technology providers.

 

Chapter 11 presents details on various investments and grants received by companies focused in the area of T-cell immunotherapy. The analysis highlights the growing interest from the VC community and other strategic investors.

 

Chapter 12 provides detailed company profiles of the leading players in the market. Each company profile includes information such as financial performance, geographical presence, T-cell immunotherapy pipeline, recent collaborations and developments. Additionally, we have also provided details about funding instances relevant to each player.

 

Chapter 13 is a collection of transcripts of interviews conducted during the course of this study.

 

Chapter 14 summarises the overall report. In this chapter, we have provided a list of key takeaways and have expressed our independent opinion based on the research and analysis described in previous chapters.

 

Chapters 15 is an appendix, which provides tabulated data and the list of companies covered in the report.

 

 
1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2 EXECUTIVE SUMMARY
 
3 INTRODUCTION
3.1. Chapter Overview
3.2. The Four Pillars of Cancer Therapy
3.3. Immunotherapy: Gaining a Strong Foothold
3.4. Immuno-Oncology (Cancer Immunotherapy)
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1 Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Cell Based Therapies
3.6. T-Cell Therapies: Historical Evolution
3.7. T-Cell Therapies: Key Considerations
3.8. Strategies for Redirection of T-Cells
3.9. Methodologies for Transduction / Transfection of T-Cells
3.9.1. Retroviral Vectors
3.9.2. Lentiviral Vectors
3.9.3. Sleeping Beauty Transposon
3.10. Curative Potential of T-Cell Therapies
3.11. Roadblocks for T-Cell Therapies
 
4 MARKET LANDSCAPE
4.1. Introduction
4.2. Evolving T-Cell Therapy Space
4.3. T-Cell Therapy: A Promising and Robust Pipeline
4.4. CAR-T Cells Spearhead the T-Cell Market
4.5. Academia Research Leads On-going Activity in the T-Cell Space
4.6. T-Cell Market Poised to Expand Further: Several Molecules in Early Phases of Development
4.7. LimitedSuccess So Far: Restricted to Haematological Cancers/ Solid Tumours
4.8. Active Industry Players in the T-Cell Therapy Market
4.9. CD19 Continues to be the Most Popular Target for CAR-T Therapies
4.10. Targets Well Distributed for TCR Therapies
4.11. Other T-Cell Immunotherapies under Development
 
5 CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY
5.1. Introduction
5.2. History of Development
5.3. Current Research Landscape
5.4. Anatomical Layout of Chimeric Antigen Receptor
5.5. Generations of Chimeric Antigen Receptors
5.6. Development of CAR-T Cells
5.7. Lymphodepleting Therapy
5.8. Universal CAR-Ts
5.9. Route of Administration
5.10. Toxicity Issues
5.10.1. Cytokine Release Syndrome (CRS)
5.10.2. On-Target Off-Tumour Toxicity
5.10.3. Encephalopathy and B-Cell Aplasia
5.11. Management of Toxicity Issues 
5.11.1. Target Selection
5.11.2. Cell Persistence
5.11.3. Receptor Expression
5.12. CD19:  An Attractive Target 
5.13. Other Targets 
5.14. Challenges Associated with CAR-T Therapy
5.14.1. Competitive Risks
5.14.2. Clinical Risks
5.14.3. Regulatory Challenges
5.14.4. Commercial Risks
 
5.15. CTL019 (Novartis)
5.15.1. Introduction
5.15.2. History of Development
5.15.3. Development Status
5.15.4. Key Clinical Trial Results
5.15.5. Dosage Regimen, Treatment Cost and Manufacturing
 
5.16. JCAR (Juno Therapeutics)
5.16.1. Introduction
5.16.2. CAR-T Design
5.16.3. Development Status
5.16.4. Key Clinical Trial Results
5.16.4.1. JCAR014
5.16.4.2. JCAR015
5.16.4.3. JCAR017
5.16.5. Dosage Regimen and Manufacturing
 
5.17. KTE-C19 (Kite Pharma)
5.17.1. Introduction
5.17.2. Development Status
5.17.3. Key Clinical Trial Results
5.17.4. Dosage Regimen and Manufacturing
5.17.5. Next Generation eACT CAR Candidates
 
5.18. CD19 CAR (Takara Bio)
5.18.1. Introduction
5.18.2. Development Status
5.18.3. Key Clinical Trial Results
5.18.4. Dosage Regimen and Manufacturing
 
5.19. EFGRvIII CAR (Kite Pharma)
5.19.1. Introduction
5.19.2. Development Status
5.19.3. Dosage Regimen and Manufacturing
 
6 T-CELL RECEPTOR (TCR) THERAPIES
6.1. Introduction
6.2. Structure of T-Cell Receptor
6.3. Difference between CAR and TCR
6.4. History of Development
6.5. Current Research Landscape
6.6. Mechanism of Action
6.7. Safety Issues 
6.7.1. Insertional Mutagenesis
6.7.2. On-Target Off-Tumour Toxicity
6.7.3. Cross Reactivity Issues
6.7.4. TCR Mismatch Pairing
6.8. Prerequisites of Antigen-Specific T-Cell Receptors 
6.9. Identifying Strategies that Enhance the Anti-Tumour Efficacy 
6.9.1. Affinity Enhanced TCRs
6.9.2. Soluble TCR Based Biologics
 
6.10. NY-ESO-1 TCR (Kite Pharma)
6.10.1. Introduction
6.10.2. Development Status
6.10.3. Dosage Regimen
 
6.11. MAGE A3/A6 TCR (Kite Pharma)
6.11.1. Introduction
6.11.2. Development Status
6.11.3. Dosage Regimen
 
6.12. JTCR016 (Juno Therapeutics)
6.12.1. Introduction
6.12.2. Development Status
6.12.3. Key Clinical Trial Results
6.12.4. Dosage Regimen
 
6.13. IMCgp100 (Immunocore)
6.13.1. Introduction
6.13.2. Development Status
6.13.3. Key Clinical Trial Results
6.13.4. Dosage Regimen
 
7. TUMOUR INFILTRATING LYMPHOCYTES (TIL) BASED THERAPIES
7.1. Introduction
7.2. Historical Background
7.3. Current Research Landscape
7.4. Strategies under Research to Enhance Efficacy 
7.5. TIL: A Prognostic Tool for Various Indications
 
7.6. LN-144 (Formerly Contego) (Lion Biotechnologies)
7.6.1. Introduction
7.6.2. Development Status
7.6.3. Key Clinical Trial Results
7.6.4. Dosage Regimen and Manufacturing
7.6.5. Patent Portfolio
 
8. MARKET OPPORTUNITY
8.1. Chapter Overview
8.2. Scope and Limitations
8.3. Forecast Methodology
8.4. Overall T-Cell Therapy Market, 2015-2030
 
8.5. Overall Chimeric Antigen Receptor T-Cell (CAR-T) Market
8.5.1. CTL019 (Novartis)
8.5.1.1. Target Population
8.5.1.2. Sales Forecast
 
8.5.2. KTE-C19 (Kite Pharma)
8.5.2.1. Target Population
8.5.2.2. Sales Forecast
 
8.5.3. CD19 CAR-T (Takara Bio)
8.5.3.1. Target Population
8.5.3.2. Sales Forecast
 
8.5.4. EGFR CAR-T (Cellular Biomedicine Group)
8.5.4.1. Target Population
8.5.4.2. Sales Forecast
 
8.5.5. CD30 CAR-T (Cellular Biomedicine Group)
8.5.5.1. Target Population
8.5.5.2. Sales Forecast
 
8.5.6. Anti-CD19 CAR-T VectorTransducedT-Cells (Cellular Biomedicine Group)
8.5.6.1. Target Population
8.5.6.2. Sales Forecast
 
8.5.7. Anti-CD20 CAR T VectorTransduced T-Cells (Cellular Biomedicine Group)
8.5.7.1. Target Population
8.5.7.2. Sales Forecast
 
8.5.8. CD19 EBV CAR-T (Autolus)
8.5.8.1. Target Population
8.5.8.2. Sales Forecast
 
8.5.9. EGFRvIII (Kite Pharma)
8.5.9.1. Target Population
8.5.9.2. Sales Forecast
 
8.5.10. JCAR017 (Juno Therapeutics)
8.5.10.1. Target Population
8.5.10.2. Sales Forecast
 
8.5.11. JCAR0XX (Juno Therapeutics)
8.5.11.1. Target Population
8.5.11.2. Sales Forecast
 
8.6. Overall TCR Market
8.6.1. IMCgp100 (Immunocore)
8.6.1.1. Target Population
8.6.1.2. Sales Forecast
 
8.6.2. NY-ESO-1 TCR (Kite Pharma)
8.6.2.1. Target Population
8.6.2.2. Sales Forecast
 
8.6.3. HPV-16 E6-TCR (Kite Pharma)
8.6.3.1. Target Population
8.6.3.2. Sales Forecast
 
8.6.4. NY-ESO-1 TCR (Adaptimmune)
8.6.4.1. Target Population
8.6.4.2. Sales Forecast
 
8.6.5. ALT-801 (Altor BioScience)
8.6.5.1. Target Population
8.6.5.2. Sales Forecast
 
8.6.6. WT-1 TCR (Cell Therapy Catapult)
8.6.6.1. Target Population
8.6.6.2. Sales Forecast
 
8.6.7. JTCR016 (Juno Therapeutics)
8.6.7.1. Target Population
8.6.7.2. Sales Forecast
 
8.6.8. MAGE A3/A6 (Kite Pharma)
8.6.8.1. Target Population
8.6.8.2. Sales Forecast
 
8.6.9. MAGE A3 (Kite Pharma)
8.6.9.1. Target Population
8.6.9.2. Sales Forecast
 
8.7. Overall TIL Therapy Market
8.7.1. LN-144 (Lion Biotechnologies)
8.7.1.1. Target Population
8.7.1.2. Sales Forecast
 
8.7.2. TIL Therapy (Nantes University)
8.7.2.1. Target Population
8.7.2.2. Sales Forecast
 
8.7.3. TIL Therapy (Netherlands Cancer Institute)
8.7.3.1. Target Population
8.7.3.2. Sales Forecast
 
9. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES
9.1. Chapter Overview
9.2. Introduction
 
9.3. Haematological Malignancies
9.3.1. Leukaemia and Lymphoma
9.3.1.1. Introduction and Epidemiology: Leukaemia
9.3.1.1.1. Acute Myeloid Leukaemia (AML)
9.3.1.1.2. Chronic Myeloid Leukaemia (CML)
9.3.1.1.3. Acute Lymphocytic Leukaemia (ALL)
9.3.1.1.4. Chronic Lymphocytic Leukaemia (CLL)
9.3.1.2. Introduction and Epidemiology: Lymphoma
9.3.1.3. Current Treatment Landscape
9.3.1.3.1. Targeted Therapies
9.3.1.4. T-Cell Immunotherapy and Research Landscape
9.3.1.4.1. CAR-Ts and Leukaemia/Lymphoma
9.3.1.4.2. TCRs and Leukaemia/Lymphoma
 
9.3.2. Multiple Myeloma
9.3.2.1. Introduction and Epidemiology
9.3.2.2. Current Treatment Landscape
9.3.2.3. T-Cell Immunotherapy and Research Landscape
 
9.4. Solid Tumours
9.4.1. Metastatic Melanoma
9.4.1.1. Introduction and Epidemiology
9.4.1.2. Current Treatment Landscape
9.4.1.3. T-Cell Immunotherapy and Research Landscape
9.4.1.3.1. TILs and Metastatic Melanoma
9.4.1.3.2. TIL Research at MD Cancer Research Centre, USA
9.4.1.3.3. TIL Research at Sheba Medical Centre, Israel
9.4.1.3.4. TCRs and Metastatic Melanoma
9.4.1.3.5 CAR-Ts and Metastatic Melanoma
 
9.4.2. Bladder Cancer
9.4.2.1. Introduction and Epidemiology
9.4.2.2. Current Treatment Landscape
9.4.2.3. T-Cell Immunotherapy and Research Landscape
 
9.4.3. Kidney Cancer
9.4.3.1. Introduction and Epidemiology
9.4.3.2. Current Treatment Landscape
9.4.3.3. T-Cell Immunotherapy and Research Landscape
 
9.4.4. Ovarian Cancer
9.4.4.1. Introduction and Epidemiology
9.4.4.2. Current Treatment Landscape
9.4.4.3. T-Cell Immunotherapy and Research Landscape
9.4.4.3.1. CAR-Ts and Ovarian Cancer
9.4.4.3.2. TCRs and Ovarian Cancer
 
9.4.5. Breast Cancer
9.4.5.1. Introduction and Epidemiology
9.4.5.2. Current Treatment Landscape
9.4.5.3. T-Cell Immunotherapy and Research Landscape
9.4.5.3.1. CAR-Ts and Breast Cancer
9.4.5.3.2. TCRs and Breast Cancer
9.4.5.3.3. TILs and Breast Cancer
 
9.4.6. Glioblastoma
9.4.6.1. Introduction and Epidemiology
9.4.6.2. Current Treatment Landscape
9.4.6.3. T-Cell Immunotherapy and Research Landscape
 
10 EMERGING TECHNOLOGIES
10.1. Chapter Overview
10.2. Introduction
10.3. Genome Editing Driving the T-Cell Therapies
10.4. Applications of Genome Editing
10.4.1. Genome Editing Technologies
10.4.1.1. CRISPR/Cas9 System
10.4.1.1.1. Structural Features
10.4.1.1.2. Modularity of the System
10.4.1.1.3. Mechanism of Action
10.4.1.1.4. Targeting Efficiency and Challenges
10.4.1.1.5. Next-GEN CRISPR Technology
10.4.1.1.6. Technology Providers
10.4.1.1.6.1. Editas Medicine
10.4.1.1.6.2 Intellia Therapeutics
10.4.1.1.6.3. CRISPR Therapeutics
 
10.4.1.2. TALENs
10.4.1.2.1. Structural Features
10.4.1.2.2. Mechanism of Action
10.4.1.2.3. Advantages and Challenges
10.4.1.2.4. Technology Providers
10.4.1.2.4.1. Cellectis
10.4.1.2.4.2. Editas Medicine
 
10.4.1.3. Endonuclease and megaTAL
10.4.1.3.1. Technology Providers
10.4.1.3.1.1 bluebird bio
 
10.4.1.4. Zinc Finger Nuclease
10.4.1.4.1. Benefits
10.4.1.4.2. Technology Providers
10.4.1.4.2.1. Sangamo Biosciences
 
10.5. Designing T-Cell Therapies with ImprovedCharacteristics
10.5.1. Technology for Targeting Multiple Cancers
10.5.1.1. Antibody Coupled T-Cell Receptor, UnumTherapeutics
10.5.1.2. NK Cell Receptor, Celyad
10.5.1.2.1. Long Term Tumour free Survival
10.5.1.2.2. Durable Anti-Tumour Immunity
 
10.5.2. Technology for Improved Safety
10.5.2.1. Armoured CAR, Juno Therapeutics
10.5.2.2. RheoSwitch Therapeutic System, Intrexon
10.5.2.3. Inducible Caspase9 Safety Switch, BellicumPharmaceuticals
10.5.2.3.1. CaspaCIDe Safety Switch Technology
10.5.2.3.2. CIDeCAR Switch Technology
10.5.2.3.3. GoCAR-T Switch Technology
10.5.2.4. On-Off Switch, Multiple Companies
10.5.2.4.1. Inhibitory CAR (iCAR), Juno Therapeutics
10.5.2.4.2. On-Off Switch, Theravectys
 
10.5.3. Allogeneic Technology
10.5.3.1. CIK CAR-T Cells, Formula Pharmaceuticals
10.5.3.2. Allogeneic Platform, Celyad
10.5.3.3. Allogeneic Platform, Cellectis
 
11 VENTURE CAPITAL SUPPORT
11.1. Chapter Overview
11.2. Investors and Innovative Therapies: Trending Together
11.3. Instances of Investments / Grants in T-Cell Therapies
11.4. Growing Venture Capitalist Interest
11.5. Funding Instances: Distribution by Type ofFunding
11.6. Funding Amount: Distribution by Type of Funding
 
12 COMPANY PROFILES
12.1. Chapter Overview
12.2. Adaptimmune
12.2.1. Company Overview
12.2.2. Financial Information
12.2.3. Product Portfolio
12.2.4. Manufacturing Capabilities
12.2.5. Collaborations
12.2.5.1. Progenitor Cell Therapy
12.2.5.2. Thermofisher / Life Technologies
12.2.5.3. GlaxoSmithKline
12.2.6. Future Outlook
 
12.3. Altor Bioscience Corporation
12.3.1. Company Overview
12.3.2. Financial Information
12.3.3. Product Portfolio
12.3.4. Patents Portfolio
12.3.5. Collaborations
12.3.5.1. Massachusetts General Hospital and Howard Hughes Medical Institute
12.3.6. Future Outlook
 
12.4. bluebird bio
12.4.1. Company Overview
12.4.2. Financial Information
12.4.3. Product Portfolio
12.4.4. Collaborations
12.4.4.1. Celgene Corporation
12.4.4.2. Pregenen
12.4.4.3. Five Prime Therapeutics
12.4.4.4. Kite Pharma
12.4.5. Future Outlook
 
12.5. Cellectis
12.5.1. Company Overview
12.5.2. Financial Information
12.5.3. Product Portfolio
12.5.4. Collaborations
12.5.4.1. CELLforCURE
12.5.4.2. OncoDesign Biotechnology
12.5.4.3. Ohio University
12.5.4.4. Weill Cornell Medical College
12.5.5. Future Outlook
 
12.6. Cell Therapy Catapult
12.6.1. Company Overview
12.6.2. Product Portfolio
12.6.3. Manufacturing Capabilities
12.6.4. Collaborations
12.6.4.1. UCL and Imperial Innovations
12.6.4.2. Cellular Therapeutics
12.6.5. Future Outlook
 
12.7. Juno Therapeutics
12.7.1. Company Overview
12.7.2. Financial Information
12.7.3. Product Portfolio
12.7.4. Patent Litigation
12.7.5. Manufacturing Capabilities
12.7.6. Collaborations
12.7.6.1. Memorial Sloan Kettering, Fred Hutchinson CancerCenter, Seattle Children’s Research Institute
12.7.6.2. Opus Bio
12.7.6.3. MedImmune/AstraZeneca
12.7.6.4. Stage Cell Therapeutics
12.7.6.5. Editas Medicine
12.7.6.6. Fate Therapeutics
12.7.6.7. X-Body
12.7.6.8. Celgene
12.7.7. Future Outlook
 
12.8. Kite Pharma
12.8.1. Company Overview
12.8.2. Financial Information
12.8.3. Product Portfolio
12.8.4. Manufacturing Capabilities
12.8.5. Collaborations
12.8.5.1. National Cancer Institute / National Institutes ofHealth
12.8.5.2. Cabaret Biotech
12.8.5.3. NeoStem
12.8.5.4. Amgen
12.8.5.5. Tel Aviv Sourasky Medical Center
12.8.5.6. T-Cell Factory B.V. (TCF)
12.8.5.7. bluebird bio
12.8.5.8. Leukemia and Lymphoma Society
12.8.6. Future Outlook
 
12.9. Lion Biotechnologies
12.9.1. Company Overview
12.9.2. Financial Information
12.9.3. Product Portfolio
12.9.4. Manufacturing Capabilities
12.9.5. Collaborations
12.9.5.1. Lonza
12.9.5.2. Moffitt Cancer Center
12.9.5.3. National Cancer Institute
12.9.5.4. National Institutes of Health
12.9.6. Upcoming Products: Next Generation TILs
12.9.7. Future Outlook
 
12.10. Novartis
12.10.1. Company Overview
12.10.2. Financial Information
12.10.3. Product Portfolio
12.10.4. Patent Litigation
12.10.5. Manufacturing Capabilities
12.10.6. Collaborations
12.10.6.1. University Of Pennsylvania
12.10.6.2. Oxford BioMedica
12.10.6.3. Intellia Therapeutics and Caribou Sciences
12.10.7. Future Outlook
 
12.11. Takara Bio
12.11.1. Company Overview
12.11.2. Financial Information
12.11.3. Product Portfolio
12.11.4. Manufacturing Capabilities
12.11.5. Collaborations
12.11.5.1. Memorial Sloan Kettering Cancer Center
12.11.5.2. Jichi Medical University Hospital
12.11.6. Future Outlook
 
12.12. Unum Therapeutics
12.12.1. Company Overview
12.12.2. Financial Information
12.12.3. Product Portfolio
12.12.4. Collaborations
12.12.5. Future Outlook
 
12.13. Other Companies
12.13.1. Bellicum Pharmaceuticals
12.13.2. Cellular Biomedicine Group
12.13.2.1. Product Portfolio
12.13.2.2. Collaborations
 
13 INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.1.1. Vincent Brichard, Vice President, Immuno-Oncology, Celyad
13.1.2. Peter Ho, Director, Process Development, Lion Biotechnologies
13.1.3. Aino Kalervo, Competitive Intelligence Manager - Strategy & Business Development, Theravectys
 
14 CONCLUSION
14.1. T-Cell Therapies: Unfurling Another Dimension of Immunotherapy
14.2. Collaborative Efforts of Research and Industry to Drivethe Market
14.3. Undoubtedly CAR-T Therapy is the Current Flag-Bearer
14.4. Haematological Cancers and Solid Tumours are the Key Focus Areas
14.5. Innovative Technological Platforms have Emerged as Vital Enablers
14.6. Anticipated Market Success Backed up by Progressive Pipelines and VC Funding
 
15. APPENDIX I: TABULATED DATA
      APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS 
 
 
Figure 3.1  The Four Pillars of Cancer Therapy
 
Figure 3.2 Differences between Active and Passive Immunotherapy 
 
Figure 3.3 Differences between Specific and Non-Specific Immunotherapy
 
Figure 3.4  3Es of the Immune System
 
Figure 3.5  Strategies for Redirecting T-Cells
 
Figure 3.6  Targeted Therapeutic Areas in the T-Cell Market
 
Figure 3.7  T-Cell Therapy: Benefits and Roadblocks
 
Figure 4.1  T-Cell Immunotherapy Pipeline: Distribution by Type of Product
 
Figure 4.2  T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
 
Figure 4.3  T-Cell Immunotherapy Pipeline: Distribution by Type of Developer across CAR-Ts, TCRs and TILs
 
Figure 4.4  T-Cell Immunotherapy Pipeline: Distribution by Phase of Development (Clinical/Preclinical)
 
Figure 4.5  T-Cell Immunotherapy Pipeline: Distribution by Phase of Development (PI/II/III/Preclinical)
 
Figure 4.6  T-Cell Immunotherapy Pipeline: Distribution by Phase of Development (PI/II/III/Preclinical) across CAR-Ts, TCRs and TILs
 
Figure 4.7  T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area
 
Figure 4.8  T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area across CAR-Ts, TCRs and TILs
 
Figure 4.9  T-Cell Immunotherapy Pipeline: Active Industry Players in Clinical Development
 
Figure 4.10 T-Cell Immunotherapy Pipeline: Active Industry Players in Preclinical Development
 
Figure 4.11  CAR-T Cell Therapy Pipeline: Distribution by Target Antigens
 
Figure 4.12  TCR Therapy Pipeline: Distribution by Target Antigens
 
Figure 5.1   Historical Timeline: Development of CAR-T cells 
 
Figure 5.2 CAR-T: Mapping Prominent Researchers
 
Figure 5.3 Development of CAR-T Cells
 
Figure 5.4 Challenges Witnessed in CAR-T Therapy
 
Figure 5.5 CTL019: Industry Sponsored Clinical Trial Design
 
Figure 5.6 CTL019: Non-Industry Sponsored Clinical Trial Design
 
Figure 5.7 JCAR Series: Clinical Trial Design
 
Figure 5.8 JCAR: Planned Clinical Trials
 
Figure 5.9 KTE-C19: Clinical Trial Design
 
Figure 5.10 Manufacturing CD19 CAR-T Cells: Process Comparison
 
Figure 5.11 CD19 CAR: Clinical Trial Design
 
Figure 5.12 EGFRvIII CAR: Clinical Trial Design 
 
Figure 6.1 TCR: Mapping Prominent Researchers
 
Figure 6.2 Development of TCR Based Therapies
 
Figure 6.3 NY-ESO-TCR: Clinical Trial Design
 
Figure 6.4 MAGE A3/A6 TCR: Clinical Trial Design
 
Figure 6.5 JTCR016: Clinical Trial Design
 
Figure 6.6 IMCgp100: Clinical Trial Design
 
Figure 7.1 TIL: Mapping Prominent Researchers
 
Figure 7.2  Process of Adoptive T-Cell Therapy Using TILs
 
Figure 7.3  LN-144: Clinical Trial Design
 
Figure 8.1  Overall T-Cell Therapy Market (USD Million)
 
Figure 8.2  T-Cell Therapy Market, Share of Sub-segments: Base Scenario 2020, 2025 and 2030 (USD Million)
 
Figure 8.3  Overall CAR-T Market Forecast: Base Scenario (USD Million)
 
Figure 8.4 CTL019: Current Status by Highest Phase of Development
 
Figure 8.5  CTL019 Sales Forecast: Base Scenario (USD Million)
 
Figure 8.6 KTE-C19: Current Status by Highest Phase of Development
 
Figure 8.7  KTE-C19 Sales Forecast: Base Scenario (USD Million)
 
Figure 8.8  CD 19 CAR-T Sales Forecast: Base Scenario (USD Million)
 
Figure 8.9  EGFR CAR-T Sales Forecast: Base Scenario (USD Million)
 
Figure 8.10  CD30 CAR-T Sales Forecast: Base Scenario (USD Million)
 
Figure 8.11  Anti-CD19 CAR-T Vector Transduced T-Cells Sales Forecast: Base Scenario (USD Million)
 
Figure 8.12  Anti-CD20 CAR-T Vector Transduced T-Cells Sales Forecast: Base Scenario (USD Million)
 
Figure 8.13  CD19 EBV CAR-T Sales Forecast: Base Scenario (USD Million)
 
Figure 8.14  EGFRvIII Sales Forecast: Base Scenario (USD Million)
 
Figure 8.15  JCAR017 Sales Forecast: Base Scenario (USD Million)
 
Figure 8.16  JCAR0XX Sales Forecast: Base Scenario (USD Million)
 
Figure 8.17  Overall TCR Market Forecast: Base Scenario (USD Million)
 
Figure 8.18 IMCgp100: Current Status by Highest Phase of Development
 
Figure 8.19  IMCgp100 Sales Forecast: Base Scenario (USD Million)
 
Figure 8.20 NY-ESO-1 TCR Sales Forecast: Base Scenario (USD Million)
 
Figure 8.21  HPV-16E6-TCR Sales Forecast: Base Scenario (USD Million)
 
Figure 8.22 NY-ESO-1 TCR: Current Status by Highest Phase of Development
 
Figure 8.23  NY-ESO-1 TCR Sales Forecast: Base Scenario (USD Million)
 
Figure 8.24  ALT-801 Sales Forecast: Base Scenario (USD Million)
 
Figure 8.25  WT-1 TCR Sales Forecast: Base Scenario (USD Million)
 
Figure 8.26 JTCR016: Current Status by Highest Phase of Development
 
Figure 8.27  JTCR016 Sales Forecast: Base Scenario (USD Million)
 
Figure 8.28  MAGE A3/A6 Sales Forecast: Base Scenario (USD Million)
 
Figure 8.29  MAGE A3 Sales Forecast: Base Scenario (USD Million)
 
Figure 8.30  Overall TIL Market Forecast: Base Scenario (USD Million)
 
Figure 8.31  LN-144 Sales Forecast: Base Scenario (USD Million)
 
Figure 8.32  TIL Therapy (Nantes University) Sales forecast: Base Scenario (USD Million)
 
Figure 8.33  TIL Therapy (Netherland University) Sales Forecast: Base Scenario (USD Million)
 
Figure 9.1  Most Common Types of Leukaemia
 
Figure 9.2  Leukaemia: Global Epidemiological Distribution
 
Figure 9.3  Lymphoma: Global Epidemiological Distribution
 
Figure 9.4  Multiple Myeloma: Global Epidemiological Distribution
 
Figure 9.5 Melanoma: Global Epidemiological Distribution
 
Figure 9.6 Bladder Cancer: Global Epidemiological Distribution
 
Figure 9.7  Kidney Cancer: Global Epidemiological Distribution
 
Figure 9.8  Ovarian Cancer: Global Epidemiological Distribution
 
Figure 9.9  Breast Cancer: Global Epidemiological Distribution
 
Figure10.1  Applications of Genome Editing
 
Figure 10.2  Emerging Genome Editing Technologies
 
Figure 10.3  Emerging Design Technologies
 
Figure 10.4  Properties of Enhanced T-Cell Platform
 
Figure 10.5  Comparative Landscape: CAR-T Platforms
 
Figure 11.1  T-Cell Therapies Funding: Cumulative Number of Investments by Year, 2007-2015
 
Figure 11.2  T-Cell Therapies Funding: Cumulative Amount Invested by Year, 2007-2015 (USD Million)
 
Figure 11.3 T-Cell Therapies Funding: Distribution of Instances by Type of Funding
 
Figure 11.4  T-Cell Therapies Funding: Distribution of Amount Invested by Type of Funding (USD Million)
 
Figure 12.1  Adaptimmune: VC Funding Instances (USD Million)
 
Figure 12.2 Altor BioScience: VC Funding Instances (USD Million)
 
Figure 12.3 Cellectis: VC Funding Instances (USD Million)
 
Figure 12.4 Juno Therapeutics: VC Funding Instances (USD Million)
 
Figure 12.5 Kite Pharma: VC Funding Instances (USD Million)
 
Figure 12.6 Novartis: Sales, 2009-2014 (USD Billion)
 
Figure 12.7 Novartis: Sales by Operating Segments, 2014 (USD Billion)
 
Figure 12.8 Takara Bio: Sales, 2010-2014 (YEN Million)
 
Figure 12.9 Takara Bio: Sales by Operating Segments, 2014(YEN Million, %)
 
Figure 12.10 Unum Therapeutics: VC Funding Instances (USD Million)
 
Figure 12.11 Treatment Process Followed Using the Antibody Coupled T-Cell Receptor (ACTR) Technology
 
Figure 14.1 T-Cell Therapy Market Landscape: Industry Participants
 
Figure 14.2 T-Cell Therapy Market Landscape: Non-Industry Participants
 
Figure14.3 T-Cell Immunotherapy Market Forecast: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
 
 
Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
 
Table 3.2 Features of Retrovirus
 
Table 3.3 Features of Lentivirus
 
Table 4.1 T-Cell Immunotherapy Pipeline
 
Table 4.2 Other T-Cell Immunotherapeutics under Development
 
Table 5.1 Key Characteristics of CAR-T cells
 
Table 5.2 Comparison between 1st and 2nd Generation CARs
 
Table 5.3 Grading Criteria for CRS
 
Table 5.4 Safety Switches under Development for CAR-T Therapy
 
Table 5.5 CD19 CAR-T Cells: Preclinical Results
 
Table 5.6 Other Targets under Clinical/Preclinical Studies for CAR-T Therapy
 
Table 5.7 CTL019: Current Status of Development
 
Table 5.8 JCAR Series: Molecules in Clinical Development 
 
Table 5.9 JCAR Series: CAR-T Design
 
Table 5.10 JCAR: Current Status of Development
 
Table 5.11 JCAR: Dosage Regimen
 
Table 5.12 KTE-C19: Current Status of Development
 
Table 5.13 CD19 CAR: Current Status of Development
 
Table 5.14 EGFRvIII CAR-T: Current Status of Development
 
Table 6.1 Differences between CAR-T and TCR Based Therapies
 
Table 6.2 NY-ESO-1 TCR: Current Status of Development
 
Table 6.3 MAGE A3/A6: Current Status of Development
 
Table 6.4 JTCR016: Current Status of Development
 
Table 6.5 IMCgp100: Current Status of Development
 
Table 7.1 LN-144: Current Status of Development
 
Table 7.2 Patent Portfolio
 
Table 8.1 T-Cell Immunotherapy: Market Potential of Candidates
 
Table 9.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
 
Table 9.2 Comparison of Marketed Targeted Therapeutics: Leukaemia
 
Table 9.3 Comparison of Marketed Targeted Therapeutics: Lymphoma
 
Table 9.4 Targets under Investigational Trials: Leukaemia
 
Table 9.5 Targets under Investigational Trials:Lymphoma
 
Table 9.6 Comparison of Marketed Targeted Therapeutics: Multiple Myeloma
 
Table 9.7 Targets under Investigational Trials:Multiple Myeloma
 
Table 9.8 Comparison of Marketed Targeted Therapeutics: Melanoma
 
Table 9.9 Historical Development of TIL Treatment Protocols at the National Cancer Institute
 
Table 9.10 Comparison of Marketed Targeted Therapeutics: Renal Cell Carcinoma
 
Table 9.11 Comparison of Marketed Therapeutics: Breast Cancer
 
Table 9.12 Targets under Investigational Trials:Breast Cancer
 
Table 10.1 CRISPR/Cas9: Research Publications, 2014/2015
 
Table 10.2 Editas Medicine: Funding Details
 
Table 10.3 Editas Medicine: Collaborations
 
Table 10.4 Intellia Therapeutics: Research Publications on CRISPR/Cas9
 
Table 10.5 Intellia Therapeutics: Funding Details
 
Table 10.6 Intellia Therapeutics: Collaborations
 
Table 10.7 CRISPR Therapeutics: Research Publications on CRISPR/Cas9 
 
Table 10.8 CRISPR Therapeutics: Funding Details
 
Table 10.9 Cellectis: Funding Details
 
Table 10.10 Cellectis: Collaborations
 
Table 10.11 bluebird bio: Funding Details
 
Table 10.12 bluebird bio: Collaborations
 
Table 10.13 Unum Therapeutics: Funding Details
 
Table 10.14 Unum Therapeutics: Collaborations
 
Table 10.15 Intrexon: Funding Details
 
Table 10.16 Intrexon: Collaborations
 
Table 10.17 Switch Technologies: Research Publications from Bellicum Pharmaceuticals
 
Table 10.18 Bellicum Pharmaceuticals: Funding Details
 
Table 10.19 Theravectys: Funding Details
 
Table 11.1 List of Funding Rounds/Grants and Investors Involved
 
Table 12.1 Adaptimmune: T-Cell Immunotherapy Pipeline
 
Table 12.2 Adaptimmune: T-Cell Immunotherapy Collaborations
 
Table 12.3 Altor BioScience: T-Cell Immunotherapy Pipeline
 
Table 12.4 Altor BioScience: T-Cell Immunotherapy Collaborations
 
Table 12.5 bluebird bio: T-Cell Immunotherapy Pipeline
 
Table 12.6 bluebird bio: T-Cell Immunotherapy Collaborations
 
Table 12.7 Cellectis: T-Cell Immunotherapy Pipeline
 
Table 12.8 Cellectis: T-Cell Immunotherapy Collaborations
 
Table 12.9 Cell Therapy Catapult: T-Cell Immunotherapy Pipeline
 
Table 12.10 Cell Therapy Catapult: T-Cell Immunotherapy Collaborations
 
Table 12.11 Juno Therapeutics: T-Cell Immunotherapy Pipeline
 
Table 12.12 Juno Therapeutics: T-Cell Immunotherapy Collaborations
 
Table 12.13 Kite Pharma: T-Cell Immunotherapy Pipeline
 
Table 12.14 Kite Pharma: T-Cell Immunotherapy Collaborations
 
Table 12.15 Lion Biotechnologies: T-Cell Immunotherapy Pipeline
 
Table 12.16 Lion Biotechnologies: T-Cell Immunotherapy Collaborations
 
Table 12.17 Novartis: T-Cell Immunotherapy Pipeline
 
Table 12.18 Novartis: T-Cell Immunotherapy Collaborations
 
Table 12.19 Takara Bio: T-Cell Immunotherapy Pipeline
 
Table 12.20 Takara Bio: T-Cell Immunotherapy Collaborations
 
Table 12.21 Unum Therapeutics: T-Cell Immunotherapy Pipeline
 
Table 12.22 Unum Therapeutics: T-Cell Immunotherapy Collaborations
 
Table 12.23 Bellicum Pharmaceuticals: T-Cell Immunotherapy Pipeline
 
Table 12.24 Cellular Biomedicine Group: T-Cell Immunotherapy Pipeline
 
Table 12.25 Cellular Biomedicine Group: T-Cell Immunotherapy Collaborations
 
Table 15.1 T-Cell Therapy Pipeline: Distribution by Type of Product
 
Table 15.2 T-Cell Therapy Pipeline: Distribution by Type of Developer
 
Table 15.3 T-Cell Immunotherapy Pipeline: Comparison of Distribution by Type of Developer across CAR-Ts, TCRs and TILs
 
Table 15.4 T-Cell Therapy Pipeline: Distribution by Phase of Development (Clinical/Preclinical)
 
Table 15.5 T-Cell Therapy Pipeline: Distribution by Phase of Development (PI/II/III/Preclinical)
 
Table 15.6 T-Cell Therapy Pipeline: Comparison of Distribution by Phase of Development (PI/II/III/Preclinical) across CAR-Ts, TCRs and TILs
 
Table 15.7 T-Cell Therapy Pipeline: Distribution by Target Therapeutic Area
 
Table 15.8 T-Cell Therapy Pipeline: Comparison of Distribution by Target Therapeutic Area across CAR-Ts, TCRs and TILs
 
Table 15.9 T-Cell Therapy: Active Players in Clinical Development
 
Table 15.10 T-Cell Therapy: Active Players in Preclinical Development
 
Table 15.11 CAR-T Therapy: Distribution by Targets
 
Table 15.12 TCR Therapy: Distribution by Targets
 
Table 15.13 Overall T-Cell Therapy Market (USD Million)
 
Table 15.14 T-Cell Therapy Market, Share of Sub-segments: 2020, 2025 and 2030 (USD Million)
 
Table 15.15 Overall CAR-T Market Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.16 CTL019 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.17 KTE-C19 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.18 CD 19 CAR T Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.19 EGFR CAR-T Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.20 CD30 CAR-T Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.21 Anti-CD19 CAR-T Vector Transduced T-Cells Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.22 Anti-CD20 CAR-T Vector Transduced T-Cells Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.23 CD19 EBV CAR-T Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.24 EGFRvIII Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.25 JCAR017 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.26 JCAR0XX Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.27 Overall TCR Market Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.28 IMCgp100 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.29 NY-ESO-1 TCR Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.30 HPV-16E6-TCR Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.31 NY-ESO-1 TCR Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.32 ALT-801 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.33 WT-1 TCR Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.34 JTCR016 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.35 MAGE A3/A6 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.36 MAGE A3 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.37 Overall TIL Market Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.38 LN-144 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.39 TIL Therapy (Nantes University) Sales forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.40 TIL Therapy (Netherlands University) Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
 
Table 15.41 T-Cell Therapies Funding: Cumulative Number of Investments by Year, 2007-2015
 
Table 15.42 T-Cell Therapies Funding: Cumulative Amount Invested by Year, 2007-2015 (USD Million)
 
Table 15.43 T-Cell Therapies Funding: Distribution of Instances by Type of Funding
 
Table 15.44 T-Cell Therapies Funding: Distribution of Amount Invested by Type of Funding (USD Million)
 
Table 15.45 Adaptimmune: VC Funding Instances (USD Million)
 
Table 15.46 Altor BioScience: VC Funding Instances (USD Million)
 
Table 15.47 bluebird bio: VC Funding Instances (USD Million)
 
Table 15.48 Cellectis: VC Funding Instances (USD Million)
 
Table 15.49 Juno Therapeutics: VC Funding Instances (USD Million)
 
Table 15.50 Kite Pharma: VC Funding Instances (USD Million))
 
Table 15.51 Novartis: Sales, 2010-2014 (USD Million)
 
Table 15.52 Novartis: Sales by Operating Segments, 2014 (USD Million)
 
Table 15.53 Takara Bio: Sales, 2010-2014 (YEN Million)
 
Table 15.54 Takara Bio: Sales by Operating Segments, 2014 (YEN Million)
 
Table 15.55 Unum Therapeutics: VC Funding Instances (USD Million)
 
Table 15.56 T-Cell Immunotherapy Market Forecast: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
 

 

Following companies and organisations have been mentioned in this report.

  1. Abingworth
  2. Abramson Cancer Center, University of Pennsylvania 
  3. Acorn Campus Ventures
  4. Adaptimmune
  5. AFA Försäkring
  6. AGF Private Equity
  7. AgonOx
  8. Agreen Biotech
  9. Aju IB Investment
  10. Alaska Permanent Fund
  11. Alexandria Ventures
  12. Allos Therapeutics
  13. Altor BioScience
  14. Amgen
  15. Applied Immune Technologies
  16. Aquilo Capital Management
  17. ARCH Venture Partners
  18. Artax Biopharma
  19. AstraZeneca
  20. Atara Biotherapeutics
  21. Atlas Venture
  22. Autolus (spin off from UCL)
  23. AVG Ventures
  24. Banca Esperia
  25. BankInvest Biomedical Venture
  26. Bayer
  27. Baylor College of Medicine
  28. Bellicum Pharmaceuticals
  29. Bezos Expeditions
  30. Biogen
  31. BioNTech
  32. Biotecnol
  33. bluebird bio
  34. Bpifrance
  35. Brace Pharma Capital
  36. Bristol-Myers Squibb
  37. Broad Institute
  38. Broadfin Capital
  39. Cabaret Biotech
  40. California Institute for Regenerative Medicine
  41. California Institute of Technology
  42. California Stem Cell Agency
  43. Cancer Prevention and Research Institute of Texas
  44. Caribou Sciences
  45. CARsgen
  46. Casdin Capital
  47. Catalyst
  48. Celdara
  49. Celgene
  50. Cell Therapy Catapult
  51. Cellectis
  52. CELLforCURE
  53. Cellular Biomedicine Group
  54. Cellular Therapeutics
  55. Celyad
  56. Children with Leukaemia
  57. Chinese PLA General Hospital
  58. City of Hope Medical Center
  59. CLL Global Research Foundation Alliance
  60. Cold Genesys
  61. Conkwest
  62. Cowen Investment
  63. CRISPR Therapeutics
  64. CrunchFund
  65. Cyto Pulse
  66. Dartmouth College
  67. Deerfield Partners
  68. Dendreon Corporation
  69. Deutsche Krebshilfe
  70. Duke University
  71. Easton Capital
  72. EcoR1 Capital
  73. Editas Medicine
  74. Edmond Venture Capital
  75. Ehime University
  76. Eisai
  77. Eli Lilly
  78. Endocyte
  79. Erasmus University
  80. Eureka Therapeutics
  81. Fate Therapeutics
  82. Felicis Ventures
  83. Fidelity Biosciences
  84. Fiverings Co.
  85. Flagship Ventures
  86. Forbion Capital Partners
  87. Foresite Capital
  88. Formula Pharmaceuticals
  89. Fred Hutchinson Cancer Research Center
  90. Fujita Health University
  91. GammaCell Biotechnologies
  92. Genentech
  93. Genzyme (Sanofi)
  94. Genzyme Ventures
  95. Gilead Sciences
  96. GlaxoSmithKline
  97. Google Ventures
  98. Griffin Securities
  99. H. Lee Moffitt Cancer Center and Research Institute
  100. Harbinger Venture Capital
  101. Harvard University
  102. Healthcare investment company Syncona
  103. Heat Biologics
  104. Herlev Hospital
  105. High Line Venture Partners
  106. ImmunoCellular Therapeutics
  107. Immunocore
  108. Imperial Innovations
  109. IMS Health Capital
  110. Innovative Genome Initiative
  111. Intellia Therapeutics
  112. Intrexon
  113. Iowa State University
  114. Jannsen Biotech
  115. Jennison Associates
  116. Jichi Medical University
  117. JMP Securities
  118. John Hopkins University
  119. John Wayne Cancer Institute
  120. Jonsson Comprehensive Cancer Center
  121. JP Moulton Charitable Foundation
  122. Juno Therapeutics
  123. Karolinska University Hospital
  124. Keio University, School of Medicine
  125. Khosla Ventures
  126. Kite Pharma
  127. Leiden University Medical Center
  128. Leukemia and Lymphoma Society
  129. Ligand Pharmaceuticals
  130. Lion Biotechnologies
  131. Lonza Biologics
  132. Loyola University
  133. M.D. Anderson Cancer Center
  134. Massachusetts Institute of Technology
  135. MaxCyte
  136. Mayo Clinic
  137. Medigene
  138. Memorial Sloan Kettering Cancer Center
  139. Merck
  140. Merck Serono
  141. Mie University
  142. Millennium Pharmaceuticals
  143. MolMed
  144. Monash University
  145. Morphotek
  146. Mustang Therapeutics
  147. Nagoya University
  148. Nantes University Hospital
  149. Nantworks
  150. National Cancer Institute
  151. National Institute of Health
  152. National University of Singapore
  153. NeoStem
  154. New Enterprise Associates (NEA)
  155. New Leaf Venture
  156. Novartis
  157. Novartis Institute for Biomedical Research (NIBR)
  158. Novo A/S
  159. Oberland Capital Healthcare
  160. ODYSSEE Venture
  161. Ohio University
  162. Omega Funds
  163. Oncodesign Biotechnology
  164. OnCyte
  165. Ono Pharmaceutical Co.
  166. Onyx Pharmaceuticals
  167. Opexa Therapeutics
  168. Opus Bio
  169. OrbiMed Advisors
  170. Oxford BioMedica
  171. Partners Innovation Fund
  172. Pasteur Institute
  173. Peking University
  174. Perceptive Advisors   
  175. Peter MacCallum Cancer Centre, University of Melbourne
  176. Pfizer
  177. Pharmacyclics
  178. Polaris Partners
  179. Pontifax
  180. Precision Biosciences/Pregenen
  181. Precision Genome Engineering
  182. Progenitor Cell Therapy
  183. Pure MHC
  184. QueensBridge Venture Partners
  185. Quogue Capital
  186. QVT Financial
  187. RA capital Management
  188. Ramius Capital Group
  189. Redmile Group
  190. Remeditex Ventures
  191. Renji Hospital
  192. Ridgeway Capital Partners
  193. Riverbank Capital Securities
  194. Roche
  195. Rock Spring Capital
  196. Roswell Park Cancer Institute
  197. Sabby Capital
  198. San Raffaele Hospital (OSR)
  199. Sanderling Ventures
  200. Sangamo Biosciences
  201. Sanofi-Genzyme BioVentures
  202. Seattle Children's Hospital
  203. Seattle Genetics
  204. Sectoral Asset Management
  205. Servier
  206. Shanghai Cancer Institute
  207. Sheba Medical Center
  208. Shenzhen Second People's Hospital
  209. Shionogi
  210. Silicon Valley Bank
  211. Sorrento Therapeutics
  212. Southwest Hospital
  213. Spectrum Pharmaceuticals
  214. SR One
  215. St. Jude Children’s Research Hospital
  216. Stage Cell Therapeutics
  217. Statcom Co.
  218. Suma Ventures
  219. Sun Yat-Sen University
  220. Sunol Molecular Corporation
  221. SV Angel
  222. Swedish Cancer Society
  223. T. Rowe Price Associates
  224. Takara Bio
  225. T-Cell Factory
  226. Tel Aviv Sourasky Medical Centre
  227. TETHYS
  228. Texas Children's Hospital
  229. The Children's Hospital of Philadelphia
  230. The Christie NHS Foundation Trust
  231. The Methodist Hospital System
  232. The Netherlands Cancer Institute
  233. Theravectys
  234. Thermo Fisher Scientific
  235. Third Rock Ventures
  236. Three Arch Opportunity Fund
  237. TILT Biotherapeutics
  238. TNK Therapeutics (wholly owned subsidiary of Sorrento Therapeutics)
  239. Transposagen Biopharmaceuticals
  240. TVM Capital
  241. Two Blades Foundation
  242. TxCell
  243. University College of London
  244. University Health Network
  245. University of California
  246. University of Connecticut
  247. University of Florida
  248. University of Milano-Bicocca
  249. University of Minnesota
  250. University of Oxford 
  251. Perelman School of Medicine, University of Pennsylvania
  252. University of Southern California
  253. University of Zurich
  254. Unum Therapeutics
  255. Uppsala University
  256. Valeant Pharmaceuticals
  257. venBio
  258. Venrock
  259. Versant Ventures
  260. Viking Global Investors
  261. Weill Cornell Medical College
  262. Weizmann Institute of Science
  263. Wellington Management
  264. X-Body
  265. Y Combinator
  266. Yuan Capital
  267. ZIOPHARM Oncology

 

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security